Brii Biosciences, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2041
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Adenosine Derivative and Pharmaceutical Composition Comprising the Same (US 11,793,827) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Combination Therapy for HIV with Adenosine Derivative and Capsid Inhibitors (US 11,890,297) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,128,100 | Immunogenic Compositions for Treatment of Hepatitis B In force · High confidence | In force | High confidence | |
| US 12,370,208 | Adenosine derivative and pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,793,827 | Adenosine Derivative and Pharmaceutical Composition Comprising the Same In force · High confidence | In force | High confidence | |
| US 11,890,297 | Combination Therapy for HIV with Adenosine Derivative and Capsid Inhibitors In force · High confidence | In force | High confidence | |
| US 12,257,264 | Combination Therapy for HIV with Adenosine Derivative and Capsid Inhibitors In force · High confidence | In force | High confidence | |
| US 12,390,484 | Adenosine Derivative and Pharmaceutical Composition Comprising the Same In force · High confidence | In force | High confidence | |
| US 12,370,200 | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,760,058 | Prodrugs of Neuroactive Steroids In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 4 no status recorded